Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Luca Marcomigni

Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient With High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib

Journal of Thoracic Oncology

English

Related publications

Identification of a Novel MET Exon 14 Skipping Variant Coexistent With EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment With Afatinib and Crizotinib

Journal of Thoracic Oncology

English

Complete Pathological Response to Crizotinib in a Patient With ALK-rearranged Lung Adenocarcinoma

English

Concurrent Presence of ALK Rearrangement and MET Mutation in Lung Adenocarcinoma

Journal of Thoracic Oncology

English

Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant

Journal of Thoracic Oncology

English

Carcinoma of Unknown Primary With EML4‐ALK Fusion Response to ALK Inhibitors

English

P020 Characterization of Met Exon 14 Skipping and Association With Clinical Outcomes of Crizotinib in Chinese Lung Cancers

Journal of Thoracic Oncology

English

A Case Report of an EML4-ALK-positive Elderly Non-Small Cell Lung Cancer Patient With a Poor PS Successfully Treated With Crizotinib

Japanese Journal of Lung Cancer

English

Rapid Response of Brain Metastasis to Crizotinib in a Patient With KLC1-ALK Fusion and MET Gene Amplification Positive Non-Small Cell Lung Cancer: A Case Report

Cancer Biology and Medicine

Cancer Research

Oncology

2017

English

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient With IHC-Positive and FISH-Negative ALK

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Luca Marcomigni

Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient With High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib

Related publications

Identification of a Novel MET Exon 14 Skipping Variant Coexistent With EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment With Afatinib and Crizotinib

Complete Pathological Response to Crizotinib in a Patient With ALK-rearranged Lung Adenocarcinoma

Concurrent Presence of ALK Rearrangement and MET Mutation in Lung Adenocarcinoma

Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant

Carcinoma of Unknown Primary With EML4‐ALK Fusion Response to ALK Inhibitors

P020 Characterization of Met Exon 14 Skipping and Association With Clinical Outcomes of Crizotinib in Chinese Lung Cancers

A Case Report of an EML4-ALK-positive Elderly Non-Small Cell Lung Cancer Patient With a Poor PS Successfully Treated With Crizotinib

Rapid Response of Brain Metastasis to Crizotinib in a Patient With KLC1-ALK Fusion and MET Gene Amplification Positive Non-Small Cell Lung Cancer: A Case Report

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient With IHC-Positive and FISH-Negative ALK